Yue F, Gu L, Qiu J, Oprescu S, Beckett L, Ellis J
EMBO J. 2025; .
PMID: 40065099
DOI: 10.1038/s44318-025-00397-1.
Poch A, Utzschneider D
Nat Immunol. 2025; 26(3):340-341.
PMID: 39891020
DOI: 10.1038/s41590-025-02080-3.
Liang M, Dong Q, Wu W, Fan J
Clin Rev Allergy Immunol. 2025; 68(1):8.
PMID: 39873814
DOI: 10.1007/s12016-024-09018-x.
Liu K, Li Y, Shen M, Xu W, Wu S, Yang X
Biomolecules. 2025; 15(1).
PMID: 39858465
PMC: 11764280.
DOI: 10.3390/biom15010071.
Li N, Gong Y, Zhu Y, Li B, Wang C, Wang Z
Cell Mol Life Sci. 2024; 82(1):21.
PMID: 39725781
PMC: 11671453.
DOI: 10.1007/s00018-024-05521-8.
Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity.
Qiu Y, Su Y, Xie E, Cheng H, Du J, Xu Y
Cancer Cell. 2024; 43(1):103-121.e8.
PMID: 39642888
PMC: 11756673.
DOI: 10.1016/j.ccell.2024.11.003.
Short-chain fatty acids are a key mediator of gut microbial regulation of T cell trafficking and differentiation after traumatic brain injury.
Celorrio M, Shumilov K, Ni A, Self W, Vitorino F, Rodgers R
Res Sq. 2024; .
PMID: 39606443
PMC: 11601855.
DOI: 10.21203/rs.3.rs-5397327/v1.
Modulation of the Immune Environment in Glioblastoma by the Gut Microbiota.
Green G, Cox-Holmes A, Potier A, Marlow G, McFarland B
Biomedicines. 2024; 12(11).
PMID: 39594997
PMC: 11591702.
DOI: 10.3390/biomedicines12112429.
HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells.
Shen H, Ojo O, Ding H, Mullen L, Xing C, Hossain M
Nat Commun. 2024; 15(1):9394.
PMID: 39477954
PMC: 11526104.
DOI: 10.1038/s41467-024-53593-8.
Glucose-dependent glycosphingolipid biosynthesis fuels CD8 T cell function and tumor control.
Longo J, DeCamp L, Oswald B, Teis R, Reyes-Oliveras A, Dahabieh M
bioRxiv. 2024; .
PMID: 39464161
PMC: 11507764.
DOI: 10.1101/2024.10.10.617261.
Acetylcysteine synergizes PD-1 blockers against colorectal cancer progression by promoting TCF1PD1CD8 T cell differentiation.
Zhou W, Qu M, Yue Y, Zhong Z, Nan K, Sun X
Cell Commun Signal. 2024; 22(1):503.
PMID: 39420342
PMC: 11484120.
DOI: 10.1186/s12964-024-01848-8.
Tissue niche influences immune and metabolic profiles to Staphylococcus aureus biofilm infection.
Van Roy Z, Arumugam P, Bertrand B, Shinde D, Thomas V, Kielian T
Nat Commun. 2024; 15(1):8965.
PMID: 39420209
PMC: 11487069.
DOI: 10.1038/s41467-024-53353-8.
CRISPR screens unveil nutrient-dependent lysosomal and mitochondrial nodes impacting intestinal tissue-resident memory CD8 T cell formation.
Raynor J, Collins N, Shi H, Guy C, Saravia J, Lim S
Immunity. 2024; 57(11):2597-2614.e13.
PMID: 39406246
PMC: 11590283.
DOI: 10.1016/j.immuni.2024.09.013.
Microbiota-derived acetate is associated with functionally optimal virus-specific CD8 T cell responses to influenza virus infection via GPR43-dependent metabolic reprogramming.
Qiu J, Shi C, Zhang Y, Niu T, Chen S, Yang G
Gut Microbes. 2024; 16(1):2401649.
PMID: 39388633
PMC: 11469431.
DOI: 10.1080/19490976.2024.2401649.
Metabolic mediators: microbial-derived metabolites as key regulators of anti-tumor immunity, immunotherapy, and chemotherapy.
Lu S, Wang C, Ma J, Wang Y
Front Immunol. 2024; 15:1456030.
PMID: 39351241
PMC: 11439727.
DOI: 10.3389/fimmu.2024.1456030.
Exploring the Bidirectional Effects of Gut Microbiota and Short-Chain Fatty Acids on Urticaria Subtypes Through Mendelian Randomization and Mediation Analysis.
Xiao X, Xue P, Yan X, Li Y, Shi Y, Qin H
Clin Cosmet Investig Dermatol. 2024; 17:1827-1839.
PMID: 39155883
PMC: 11328851.
DOI: 10.2147/CCID.S474422.
ACLY and ACSS2 link nutrient-dependent chromatin accessibility to CD8 T cell effector responses.
Kaymak I, Watson M, Oswald B, Ma S, Johnson B, DeCamp L
J Exp Med. 2024; 221(9).
PMID: 39150482
PMC: 11329787.
DOI: 10.1084/jem.20231820.
Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy.
Nicolini A, Ferrari P
Front Immunol. 2024; 15:1353787.
PMID: 39119332
PMC: 11306065.
DOI: 10.3389/fimmu.2024.1353787.
Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors.
Spiga M, Martini E, Maffia M, Ciceri F, Ruggiero E, Potenza A
Semin Immunopathol. 2024; 46(3-4):8.
PMID: 39060547
DOI: 10.1007/s00281-024-01011-y.
Fueling CARs: metabolic strategies to enhance CAR T-cell therapy.
Van der Vreken A, Vanderkerken K, de Bruyne E, de Veirman K, Breckpot K, Menu E
Exp Hematol Oncol. 2024; 13(1):66.
PMID: 38987856
PMC: 11238373.
DOI: 10.1186/s40164-024-00535-1.